warfarin sodium

Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to warfarin sodium: digoxin

warfarin sodium

Apo-Warfarin (CA), Coumadin, Gen-Warfarin (CA), Jantoven, Marevan (UK), Novo-Warfarin (CA), Taro-Warfarin (CA)

Pharmacologic class: Coumarin derivative

Therapeutic class: Anticoagulant

Pregnancy risk category X

FDA Box Warning

• Drug may cause major or fatal bleeding. Bleeding is more likely during starting period and with higher dosage (resulting in higher International Normalized Ratio [INR]). Monitor INR regularly in all patients. Those at high risk for bleeding may benefit from more frequent INR monitoring, careful dosage adjustment, and shorter duration of therapy. Instruct patients about measures to minimize risk of bleeding and advise them to immediately report signs and symptoms of bleeding.


Interferes with synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X) and anticoagulant proteins C and S in liver


Injection: 5.4 mg/vial (2 mg/ml when reconstituted)

Tablets: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg

Indications and dosages

Venous thrombosis; pulmonary embolism; atrial fibrillation; myocardial infarction (MI); thromboembolic complications of cardiac valve placement

Adults: Initially, 2.5 to 10 mg P.O. or I.V. daily for 2 to 4 days, then adjusted based on prothrombin time (PT) or International Normalized Ratio (INR). Usual maintenance dosage is 2 to 10 mg P.O. daily.

Dosage adjustment

• Elderly or debilitated patients

Off-label uses

• Acute coronary syndrome

• Intracoronary stent placement

• Prevention of catheter thrombosis


• Hypersensitivity to drug

• Uncontrolled bleeding

• Open wounds

• Severe hepatic disease

• Hemorrhagic or bleeding tendency

• Cerebrovascular hemorrhage

• Cerebral aneurysm or dissecting aorta

• Blood dyscrasias

• Pericarditis or pericardial effusion

• Bacterial endocarditis

• Malignant hypertension

• Recent brain, eye, or spinal cord injury or surgery

• Lumbar puncture and other procedures that may cause uncontrollable bleeding

• Major regional or lumbar block anesthesia

• Threatened abortion, eclampsia, preeclampsia

• Unsupervised senile, alcoholic, or psychotic patients

• Pregnancy, females of childbearing potential


Use cautiously in:

• cancer, heparin-induced thrombocytopenia, moderate to severe renal impairment, moderate to severe hypertension, infectious GI disease, known or suspected deficiency in protein C-mediated anticoagulant response, polycythemia vera, vasculitis, severe diabetes mellitus

• indwelling catheter use

• history of poor compliance

• elderly or debilitated patients

• breastfeeding patients

• children younger than age 18 (safety and efficacy not established).


Be aware that warfarin is a high-alert drug.

• Know that I.V. form is reserved for patients who can't tolerate oral form. I.V. and oral dosages are identical.

• For I.V. use, reconstitute vial with 2.7 ml of sterile water for injection; administer over 1 to 2 minutes. After reconstitution, drug is stable for 4 hours at room temperature.

• Be aware that vitamin K reverses warfarin effects. If major bleeding occurs, fresh frozen plasma may be given.

• When converting to warfarin from heparin, give both drugs concomitantly for 4 to 5 days until therapeutic effect of warfarin occurs.

Adverse reactions

GI: nausea, vomiting, diarrhea, abdominal cramps, stomatitis, anorexia

GU: hematuria

Hematologic: eosinophilia, bleeding, hemorrhage, agranulocytosis, leukopenia

Hepatic: hepatitis

Skin: rash, dermatitis, urticaria, pruritus, alopecia, dermal necrosis

Other: fever, "purple toes" syndrome (bilateral painful, purple lesions on toes and sides of feet), hypersensitivity reaction


Drug-drug. Abciximab, acetaminophen (chronic use), androgens, aspirin, capecitabine, cefamandole, cefoperazone, cefotetan, chloral hydrate, chloramphenicol, clopidogrel, disulfiram, eptifibatide, fluconazole, fluoroquinolones, itraconazole, metronidazole (including vaginal use), nonsteroidal anti-inflammatory drugs, plicamycin, quinidine, quinine, sulfonamides, thrombolytics, ticlopidine, tirofiban, valproic acid, zafirlukast: increased response to warfarin, greater risk of bleeding

Barbiturates, hormonal contraceptives containing estrogen: decreased anticoagulant effect

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, INR: increased values

Partial thromboplastin time, PT: prolonged

Drug-food. Vitamin K-rich foods (large amounts): antagonism of anticoagulant effect

Drug-herbs. Angelica: prolonged PT Anise, arnica, asafetida, bromelain, chamomile, clove, danshen, devil's claw, dong quai, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, licorice, meadowsweet, motherwort, onion, papain, parsley, passionflower, quassia, red clover, Reishi mushroom, rue, sweet clover, turmeric, white willow, others: increased risk of bleeding

Coenzyme Q10, green tea, St. John's wort: decreased anticoagulant effect

Drug-behaviors. Alcohol use: enhanced warfarin activity

Patient monitoring

• Monitor PT, INR, and liver function tests.

• Watch for signs and symptoms of bleeding and hepatitis.

Patient teaching

Explain therapy to patient. Stress importance of adhering to schedule for laboratory tests.

Instruct patient to promptly report unusual bleeding or bruising.

• Caution patient to consult prescriber before taking over-the-counter preparations or herbs.

• Advise patient to inform all other health care providers (including dentist) that he is taking warfarin.

• Tell patient not to vary his intake of foods high in vitamin K (such as leafy green vegetables, fish, pork, green tea, and tomatoes), to avoid alterations in drug's anticoagulant effect.

Instruct females of childbearing age to report pregnancy immediately.

• Stress importance of avoiding contact sports and other activities that could cause injury and bleeding.

• Caution patient to avoid alcohol during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.


warfarin sodium

an oral anticoagulant.
indications It is prescribed for the prophylaxis and treatment of thrombosis, atrial fibrillation, and embolism.
contraindications Pregnancy, severe renal or hepatic disease, uncontrolled hypertension, hemorrhage, hemorrhagic tendencies (e.g., due to hemophilia), leukemia, and known hypersensitivity to this drug are among the things that prohibit its use.
adverse effects The most serious adverse effect is hemorrhage. Many other drugs interact with this drug to increase or decrease its effects.

warfarin sodium

powerful anticoagulant (similar action to dicumarol); antagonizes vitamin K, interrupts normal clotting, prevents thrombus formation, prolongs bleeding time and promotes marked bruising

warfarin sodium, (wôr´fərin),

n brand names: Coumadin, Panwarfin, Sofarin;
drug class: oral anticoagulant;
action: interferes with blood clotting by indirect means; depresses hepatic synthesis of vitamin K-dependent coagulation factors (II, VII, IX, and X);
uses: pulmonary emboli, deep vein thrombosis, MI, atrial dysrhythmias.
References in periodicals archive ?
To determine the binding site of atenolol, using warfarin sodium as a Site I-specific probe, the successive steps that were followed are described below.
For example, in conjunction with the warfarin sodium product launch, Camber created a micro site, CamberWarfarin.
In controlled clinical trials comparing treatment with Innohep(R) to standard heparin therapy, including a landmark study of 435 hospitalized patients with symptomatic proximal DVT published in the New England Journal of Medicine, Innohep(R) was shown to be as safe and effective as heparin for the treatment of DVT with or without pulmonary embolism when administered in conjunction with warfarin sodium.
By manufacturing its own APIs, Taro can control both the quality and supply of its active ingredients for key products, which is especially critical for such narrow therapeutic index products as warfarin sodium tablets, phenytoin sodium capsules and carbamazepine tablets.
SG&A includes a number of marketing campaigns aimed at increasing the generic substitution rate of Taro's warfarin sodium tablets in the U.
Jantoven, the most recent item added to the cardiovascular product line at Upsher-Smith, is a warfarin sodium formulation in tablet form.
received notice from Health Canada's therapeutic products program (TPP) that its ANDA submission for nine strengths of warfarin sodium tablets USP had been approved.
0 Million in Q3 1999 -- Gross Profit Increases 33% -- 19th Consecutive Quarter of Record Sales, 8th Consecutive Quarter of Record Net Income -- Taro Granted Additional Patent for Non-Sedating Barbiturates in Q3 -- Taro's Warfarin Sodium Tablets Approved in Canada in Q3
received notification from the Therapeutic Products Program of Health Canada ("TPP") approving its Abbreviated New Drug Submission (ANDS) for nine strengths of Warfarin Sodium Tablets, USP (1mg, 2 mg, 2.
by Carbamazepine Tablets (bioequivalent to Novartis' Tegretol(R)) and Warfarin Sodium Tablets.
Sales and earnings at the rapidly growing generic drug developer and marketer are surging as the company prepares for the launch of its widely anticipated new warfarin sodium tablets, the generic equivalent of DuPont Pharma's Coumadin and potentially the most lucrative drug in Taro's history.
of all nine strengths of Taro's recently FDA-approved Warfarin Sodium Tablets USP (the generic equivalent of the brand anticoagulant Coumadin(R) tablets from Dupont Pharmaceuticals Company).

Full browser ?